Name: GHK-Cu/BPC-157/TB-500/KPV
Brand: PeptidesDirect
SKU: PD-KLOW80-80MG
Price: 115.99 EUR
Availability: InStock

Question 1

What is GHK-Cu/BPC-157/TB-500/KPV?

Accepted Answer

GHK-Cu/BPC-157/TB-500/KPV is a four-peptide research blend in a single 80 mg vial: GHK-Cu, BPC-157, TB-500 and KPV, co-lyophilized at a fixed 50:10:10:10 mass ratio. GHK-Cu is a copper-binding tripeptide, BPC-157 a 15-residue gastric peptide, TB-500 the full-length 43-amino-acid actin-binding protein thymosin beta-4, and KPV the C-terminal tripeptide of alpha-MSH. Each carries its own separate published literature; no study testing the four together was identified. Per-component amounts are on the material specification. Supplied for laboratory research only.

Question 2

How should GHK-Cu/BPC-157/TB-500/KPV be stored?

Accepted Answer

Lyophilized GHK-Cu/BPC-157/TB-500/KPV is commonly kept at -20°C for longer storage or at 2-8°C for short-term storage. Protection from light and moisture is part of the usual handling convention.

Question 3

What purity is your GHK-Cu/BPC-157/TB-500/KPV blend?

Accepted Answer

Every batch of GHK-Cu/BPC-157/TB-500/KPV ships with a certificate of analysis from Janoshik Analytical, an independent third-party laboratory. The current report covers identity and content per component; purity was not assayed on that batch, so no purity figure is stated for it. We do not run a lab ourselves: the manufacturer commissions the test, and we pass the report on unchanged, with an online verification link on the product page.

Question 4

How do the four peptides in this blend, GHK-Cu, BPC-157, TB-500 and KPV, relate to each other according to the published research?

Accepted Answer

They do not share one pathway: each of the four has its own separately studied mechanism, and no published study has combined them in one experiment. BPC-157 is described as acting through the VEGFR2 receptor and the Akt-eNOS pathway, with angiogenesis and histological tissue endpoints as readouts in rat models (PMID 40789979). TB-500, full-length thymosin beta-4, is a G-actin-sequestering peptide whose foundational mechanistic work measured endothelial and myocardial cell migration (PMID 15565145), with separate model work in mouse, rat and pig (PMID 25015963, PMID 10469335, PMID 27199757). GHK-Cu was studied for collagen synthesis (PMID 3169264) and for bFGF and VEGF output in cultured human skin fibroblasts (PMID 15655171). KPV was studied for NF-kB and MAP-kinase signalling and for colonic inflammation markers in mouse intestinal models (PMID 18061177).

Question 5

Is BPC-157, TB-500, GHK-Cu or KPV approved by the FDA, EMA, or any regulator?

Accepted Answer

None of the four peptides in this blend, BPC-157, TB-500, GHK-Cu or KPV, holds a marketing authorisation from the EMA or the FDA for any medical use; all four remain unapproved research compounds. GHK-Cu is a partial exception in that the peptide-research literature describes it as an ingredient in cosmetic products in some markets (PMID 26236730), which is a cosmetic-ingredient status rather than a drug approval. Thymosin beta-4, studied as RGN-259 and RGN-352, has been through registered human trials: the ARISE-1 to ARISE-3 programme (ClinicalTrials.gov NCT02597803, NCT02974907, NCT03937882) and a cardiac trial (NCT05984134). Neither route produced an approved drug. BPC-157 has one actively enrolling Phase 2 trial (NCT07437547) with no results reported yet.

Question 6

Is the TB-500 in this blend the full-length peptide or the short fragment some vendors sell, and does that matter?

Accepted Answer

The TB-500 in this blend is the full-length, 43-amino-acid thymosin beta-4 (molecular mass about 4963 Da, CAS 77591-33-4), the same molecule used in the cardiac, dermal and corneal studies cited for this product, not the short Ac-LKKTETQ fragment that some vendors label "TB-500." Our own third-party CoA confirms this identity for the batch we ship, which matters because the cited research (for example the phase 2 trial, PMID 25826322, and the mouse cardiac study, PMID 25015963) was conducted on the full-length peptide, and those results would not apply to the shorter fragment. Buyers should check a vendor's CoA before assuming any "TB-500" product is the studied molecule, since the two are structurally different peptides sold under the same market name.

Question 7

What does our own third-party CoA show for GHK-Cu/BPC-157/TB-500/KPV, and how can a specific batch be verified?

Accepted Answer

The most recent Janoshik report on batch White lids, tested 30 July 2026, states measured content per vial: GHK-Cu 45.99 mg, BPC-157 10.84 mg, TB-500 10.95 mg, KPV 10.74 mg. This report covers identity and amount only: the laboratory explicitly notes that peptide purity was not included in this analysis, so no purity figure is stated for this batch. Janoshik is an independent third-party laboratory, but this particular test was commissioned by the manufacturer, not by us, and we publish the report unchanged. Anyone can verify the result at verify.janoshik.com using the batch's test number 215332. If a vial shows a different batch code, that batch's own report is the one that applies.

Question 8

How does this blend differ from GHK-Cu/BPC-157/TB-500, which is sold too?

Accepted Answer

GHK-Cu/BPC-157/TB-500 is the three-peptide version: GHK-Cu, BPC-157 and TB-500, 70 mg total per vial. This blend holds those three components plus KPV, 80 mg total. KPV is the C-terminal tripeptide of alpha-MSH, studied for NF-kB and MAP-kinase signalling in mouse intestinal models (PMID 18061177). Both are co-lyophilized at a fixed ratio rather than mixed at the bench, and the literature for each shared component is the same for both products, because it comes from the same single-peptide studies. Neither has been studied as an assembled blend; the comparison sits at the level of the individual peptides.

Question 9

Why is GHK-Cu/BPC-157/TB-500/KPV sold as a fixed 50/10/10/10 mg blend instead of four separate vials?

Accepted Answer

The four peptides are co-lyophilized, combined into one powder before the vial is freeze-dried, so a single reconstitution always delivers them in the same 50:10:10:10 mg ratio and there is no way to separate them again afterwards. This is how most suppliers produce combination blends like this one and GHK-Cu/BPC-157/TB-500: it reflects research-market practice rather than a published combination study. Anyone who wants a different ratio, or wants to vary one component independently, can buy GHK-Cu, BPC-157, TB-500 and KPV separately, since we sell each on its own. We are not aware of any published study that tested whether the fixed 50:10:10:10 ratio itself has any significance beyond the four single-peptide literatures it draws on.

Question 10

Does the copper in this blend's GHK-Cu component affect how the vial looks or behaves once reconstituted?

Accepted Answer

Reconstituted GHK-Cu/BPC-157/TB-500/KPV takes on a faint blue tint from the copper in the GHK-Cu complex, which is expected and not a sign of contamination or degradation. This differs visibly from single-peptide vials like plain BPC-157 or TB-500, which reconstitute clear. We have not found any published stability study that specifically measured whether the copper complex changes the degradation rate of BPC-157, TB-500 or KPV once combined in the same vial.

GHK-Cu/BPC-157/TB-500/KPV

What is GHK-Cu/BPC-157/TB-500/KPV

Mechanism

Documentation

Storage and stability

Reviews

Frequently Asked Questions

Technical data sheet

Related research products